Actively Recruiting
A Study of MHB118C Injection in Patients With Advanced Solid Tumors
Led by Minghui Pharmaceutical (Hangzhou) Ltd · Updated on 2025-07-01
200
Participants Needed
1
Research Sites
308 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a first-in-human, open-label, multicenter Phase I study of MHB118C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MHB118C monotherapy.
CONDITIONS
Official Title
A Study of MHB118C Injection in Patients With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily agrees to participate and signs informed consent
- Age 18 years or older
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Estimated life expectancy of at least 3 months
- Able to understand and follow study procedures
- Histologically or cytologically confirmed advanced solid tumors refractory or intolerant to standard therapy, or with no standard treatment options
- At least one measurable lesion per RECIST v1.1 criteria
- Adequate organ function
You will not qualify if you...
- History of 2 or more primary cancers within 5 years before consent
- Received chemotherapy within 3 weeks or radiotherapy within 4 weeks (2 weeks for palliative bone radiotherapy) before first dose
- Received biologic, endocrine, or immunotherapy within 4 weeks before first dose
- Presence of brain metastases, leptomeningeal disease, brainstem metastases, or spinal cord compression
- Severe lung disease affecting lung function
- Active systemic infection requiring treatment within 7 days before dosing
- Serious cardiovascular or cerebrovascular diseases
- Uncontrolled third-space fluid buildup
- Known allergy to the investigational product or its components
- Drug abuse or psychiatric conditions interfering with participation
- Known alcohol or drug dependence
- Pregnant or breastfeeding, or planning to conceive
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Chest Hospital
Shanghai, China
Actively Recruiting
Research Team
V
VP of R&D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here